Drugs /

belinostat

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
belinostat
Trade Name(s):
Beleodaq
NCI Definition [1]:
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.

Clinical Trials

View Clinical Trials for belinostat

Belinostat has been investigated in 7 clinical trials, of which 6 are open and 1 is closed. Of the trials investigating belinostat, 5 are phase 1 (4 open) and 2 are phase 2 (2 open).

Complex karyotype, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for belinostat clinical trials.

Breast carcinoma, myelodysplastic syndromes, and acute myeloid leukemia are the most common diseases being investigated in belinostat clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Belinostat
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Belinostat
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating belinostat and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
belinostat, 2-propenamide, n-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, pxd 101, Beleodaq, pxd101, belinostat (substance), 414864-00-9, belinostat (product), belinostat
Drug Categories [2]:
Histone deactylase/HDAC inhibitors
Drug Target(s) [2]:
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
NCIT ID [1]:
C48812
SNOMED ID [1]:
R-FC182

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.